Evidence map›Paper›PMID 39658053›Full record

Observational studyRMD open2024

Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis.

Alexis F Guedon, Asmaa Ouafdi, Nabil Belfeki, Azeddine Dellal, Nouha Ghriss, Marc Scheen, Fadi Haidar, Olivier Espitia, Jean-Yves Scoazec, Olivier Fain and 5 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Expert Perspective: Hematologic Malignancies and Vasculitis.Arthritis & rheumatology (Hoboken, N.J.) · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alexis F Guedon *Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Paris, France guedonalexis@gmail.com.ORCID 0000-0002-4571-6219
Asmaa Ouafdi *Sorbonne Université Service de médecine interne, AP-HP, Hôpital Saint Antoine, Paris, France.
Nabil BelfekiHôpital de Melun, Service de Médecine Interne, Melun, France.
Azeddine DellalHôpital Montfermeil, Service de Médecine Interne et Rhumatologie, Montfermeil, France.
Nouha GhrissHôpital de Melun, Service de Médecine Interne, Melun, France.
Marc ScheenService de Néphrologie, Genève, Switzerland.
Fadi HaidarService de Néphrologie, Genève, Switzerland.
Olivier EspitiaNantes Université, CHU Nantes, Department of Internal and Vascular Medicine, l'institut du thorax, INSERM UMR1087/CNRS UMR 6291, Team III Vascular & Pulmonary diseases, Nantes, France.ORCID 0000-0003-0821-9990
Jean-Yves ScoazecInstitut Gustave-Roussy, Villejuif, France.
Olivier FainSorbonne Université Service de médecine interne, AP-HP, Hôpital Saint Antoine, Paris, France.
Christophe MarzacInstitut Gustave-Roussy, Villejuif, France.
Olivier HermineCEREMAST, Paris University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University Hospital, Paris, France.
Eric SolaryGustave Roussy Institute, Villejuif, France.
Julien RossignolImagine Institute, Paris, France.
Arsène MekinianSorbonne Université Service de médecine interne, AP-HP, Hôpital Saint Antoine, Paris, France.ORCID 0000-0003-2849-3049

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe aimed to assess the prevalence of clonal haematopoiesis (CH) in patients with giant cell arteritis (GCA) compared with controls and individuals with other autoimmune diseases (AIDs) and to identify high-risk clinical/genetic profiles that could influence disease outcomes.

methodsIn a prospective observational study at three hospitals, we included 49 patients diagnosed with GCA, 48 patients with other AIDs and 27 control participants. We used next-generation sequencing to detect clonal haematopoiesis (CH) among them.

resultsCH was detected in 55.1% of patients with GCA, 59.3% of controls and 18.8% of patients with other AIDs. The most commonly mutated genes in GCA and control groups were

conclusionsCH is prevalent among patients with GCA but does not differ significantly from controls or other autoimmune conditions. However, specific genetic profiles, particularly mutations in TET2 and JAK2, are associated with a higher risk cluster within the GCA cohort. This observation highlights the interest of detecting CH in patients with GCA in both routine practice and clinical trials for better risk stratification. Further prospective studies are needed to determine if management tailored to the genetic profile would improve outcomes.

Indexed as

DioxygenasesDNA-Binding ProteinsGiant Cell ArteritisJanus Kinase 2MutationProto-Oncogene ProteinsAgedAged, 80 and overAutoimmune DiseasesCase-Control StudiesClonal HematopoiesisCluster AnalysisDNA Methyltransferase 3AFemaleGenetic Predisposition to DiseaseHigh-Throughput Nucleotide SequencingDioxygenasesDNA-Binding ProteinsDNA Methyltransferase 3ADNMT3A protein, humanJAK2 protein, humanJanus Kinase 2Proto-Oncogene ProteinsTET2 protein, humanepidemiologygiant cell arteritisvasculitis

Identifiers

PMID39658053
PMCPMC11647381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.